Cost-Effectiveness Analysis of Technological Innovation for Chronic Wounds: Pharmacoeconomic Model Based on LOGIT and MAIC Tools

Author(s)

ELIO TANAKA, Sr., MD1, HENRIQUE DIEGOLI, MD2, EDUARDO Ramos, MD3, Akemi Totsugui, RESEARCHER4, Dimas Andre Milcheski, RESEARCHER4, Gabriel Kenzo Tanaka, RESEARCHER4, LUCIANA ELLWANGER, RESEARCHER5, Camila Siqueira, RESEARCHER6.
1MEDICAL AUDIT, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil, 2SURGERY, HEORVALOR, CURITIBA , PR, Brazil, 3RESEARCH, TNK, CURITIBA , PR, Brazil, 4MEDICAL AUDIT, TNK, CURITIBA PR, Brazil, 5TNK, CURITIBA PR, Brazil, 6TNK, RJ , BRASIL, Brazil.
OBJECTIVES: The objective is a cost-effectiveness analysis of a technological innovation for chronic wounds, with the aid of a pharmacoeconomic model based on the LOGIT AND MAIC tools, due to the lack of real-world information, as well as data and transparent evidence and without asymmetries for the conclusions.
METHODS: Two different situations were used for the elaboration of this study / discussion . The first in relation to accidents at work with injuries to the hands and their consequences, including mainly the evolution and possible acute to chronic wounds. And the second situation in patients with Diabetes Mellitus, who progress to a diabetic foot and a diabetic foot ulcer.
RESULTS: In the two situations studied and analysed, the suggestion to incorporate the new innovative product (dressing for chronic wounds) was important in reducing healing time, leading to savings in classic expenses, including the losses of those who do not incorporate it into the time.
CONCLUSIONS: The economic costs of hand injuries, and especially before and during the Covid-19 pandemic, are high. Larger during the pandemic, but by any standard, these injuries should be considered a substantial burden on the individual and society. The economic cost of Diabetic Foot Ulcer (DFU) is higher if not incorporating the new cost - saving innovative devices and should be considered as a substantial burden for individuals and society , just like the previous situation .

Conference/Value in Health Info

2025-05, ISPOR 2025, Montréal, Quebec, CA

Value in Health, Volume 28, Issue S1

Code

CO172

Topic

Clinical Outcomes

Topic Subcategory

Clinical Outcomes Assessment, Clinician Reported Outcomes, Comparative Effectiveness or Efficacy, Performance-based Outcomes

Disease

SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Infectious Disease (non-vaccine), SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×